Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells 151,300 Shares of Stock

Kiniksa Pharmaceuticals International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Sanj Patel sold 151,300 Kiniksa shares for about $14.33 million at an average price of $94.71. The sale was made under a pre-arranged Rule 10b5-1 plan; Patel retained 774,500 shares.
  • Kiniksa reported quarterly earnings of $0.56 per share, beating the $0.37 analyst consensus, while revenue of $285.97 million also exceeded estimates.
  • Analysts have a Moderate Buy consensus and an average price target of $100.57; shares recently traded at $93.86.
  • Five stocks to consider instead of Kiniksa Pharmaceuticals International.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CEO Sanj Patel sold 151,300 shares of the stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $94.71, for a total transaction of $14,329,623.00. Following the transaction, the chief executive officer directly owned 774,500 shares in the company, valued at approximately $73,352,895. The trade was a 16.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock traded up $5.52 on Friday, reaching $93.86. 627,284 shares of the company were exchanged, compared to its average volume of 707,415. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $98.48. The business has a 50-day moving average price of $80.18 and a 200 day moving average price of $61.10. The company has a market cap of $7.32 billion, a price-to-earnings ratio of 72.20 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. As a group, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently made changes to their positions in the stock. Allworth Financial LP grew its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the 2nd quarter. Allworth Financial LP now owns 453 shares of the company's stock valued at $29,000 after buying an additional 134 shares during the period. Curry Webb Wealth Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter worth approximately $29,000. KBC Group NV purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $34,000. Nykredit A S purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $34,000. Finally, Jacobi Capital Management LLC purchased a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $48,000. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on KNSA. Zacks Research cut Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 28th. Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a "buy" rating in a report on Wednesday, July 29th. Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, October 28th. Finally, Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.57.

Get Our Latest Report on KNSA

About Kiniksa Pharmaceuticals International

(Get Free Report)

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

Featured Articles

Insider Buying and Selling by Quarter for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?

Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.

While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines